Table S1. Baseline characteristics of NSCLC patients who underwent curative resection and who had their EGFR mutation tested after curative resection from January 2007 to December 2017.

Variable	The whole population (n=8,379)	EGFR tested (n=1,183)	P
Age (years)			0.481
≤65	6,032 (72.0%)	840 (71.0%)
>65	2,347 (28.0%)	343 (29.0%)
Sex			0.938
Female	5,274 (62.9%)	746 (63.1%)
Male	3,105 (37.1%)	437 (36.9%)
Pathologic TNM stage			0.168
I	6,123 (73.1%)	844 (71.3%)
II	1,347 (16.1%)	189 (16.0%)
III	909 (10.8%)	150 (12.7%)
Histology			0.491
Squamous carcinoma	2,053 (24.5%)	279 (23.6%)
Non-squamous carcinoma	6,326 (75.5%)	904 (76.4%)

NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor.